Recent studies have found that SPAG5 is a potential driver oncogene in a wide spectrum of cancers including breast cancer, non-small cell lung cancer, prostate cancer, cervical cancer, and bladder urothelial cancer [4,5,6,7,8,9]. Here, SPAG5 is linked to prostate cancer.